2012, Acquisition, Pricing and Study - Southern California Tech Central

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2012

Acquisition

Pricing

Study

Retrophin Drug Licensed by Shkreli Shows Positive Phase 2 Results

Xconomy

SEPTEMBER 7, 2016

Retrophin , the drug developer founded by controversial former biotech executive Martin Shkreli, has posted positive results from a midstage study for its treatment for a rare kidney disease. He licensed the drug from San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND ) in March 2012. This time, he increased the price from $13.50

San Diego

San Diego Pricing Study Journal

Evoke Pharma’s Stock Sinks on Stomach Drug’s Phase 3 Failure

Xconomy

JULY 18, 2016

In early trading Monday, Evoke’s (NASDAQ: EVOK ) stock price was down 72 percent to $3.02 Evoke’s late-stage study failed to show a significant benefit to the drug, EVK-001, versus placebo at all 41 of the sites that tested it nationally. per share as of 11:30 a.m. in New York. Evoke didn’t reveal any further plans.

Study

Study Sites News Research

Retrophin Drug Licensed by Shkreli Shows Positive Phase 2 Results

Evoke Pharma’s Stock Sinks on Stomach Drug’s Phase 3 Failure

Stay Connected